Analysts Offer Predictions for KROS FY2024 Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS) – Equities researchers at Cantor Fitzgerald issued their FY2024 earnings estimates for Keros Therapeutics in a research report issued on Thursday, October 24th. Cantor Fitzgerald analyst P. Agrawal expects that the company will post earnings per share of ($5.10) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.88) per share.

Several other research analysts have also recently issued reports on KROS. Bank of America decreased their target price on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Guggenheim initiated coverage on shares of Keros Therapeutics in a research report on Monday, September 23rd. They set a “buy” rating and a $96.00 price target for the company. Finally, Scotiabank started coverage on Keros Therapeutics in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 price objective on the stock. Eleven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $89.11.

Keros Therapeutics Price Performance

Shares of NASDAQ:KROS opened at $60.73 on Monday. Keros Therapeutics has a 1-year low of $27.31 and a 1-year high of $73.00. The business has a fifty day moving average price of $55.18 and a 200-day moving average price of $51.82. The company has a market capitalization of $2.28 billion, a PE ratio of -11.84 and a beta of 1.23.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.02). Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. The company had revenue of $0.04 million for the quarter. During the same period last year, the firm earned ($1.27) EPS.

Insider Buying and Selling

In related news, Director Carl L. Gordon sold 250,000 shares of Keros Therapeutics stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total value of $11,002,500.00. Following the completion of the sale, the director now owns 119,522 shares of the company’s stock, valued at $5,260,163.22. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 22.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Keros Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Redmile Group LLC bought a new stake in shares of Keros Therapeutics during the 1st quarter valued at $36,576,000. Darwin Global Management Ltd. grew its holdings in Keros Therapeutics by 35.4% during the first quarter. Darwin Global Management Ltd. now owns 1,435,950 shares of the company’s stock valued at $95,060,000 after purchasing an additional 375,523 shares during the period. Assenagon Asset Management S.A. increased its position in Keros Therapeutics by 814.6% in the third quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company’s stock worth $12,990,000 after buying an additional 199,245 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Keros Therapeutics by 17.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock worth $80,666,000 after buying an additional 176,803 shares during the period. Finally, Vanguard Group Inc. lifted its position in shares of Keros Therapeutics by 7.9% during the 1st quarter. Vanguard Group Inc. now owns 1,545,758 shares of the company’s stock valued at $102,329,000 after buying an additional 113,563 shares in the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.